Fastly stock posts record Q3 revenue and lifts 2026 outlook
Kemper stock: Q3 profit outlook leaves auto recovery unfinished
Prelude Therapeutics stock narrows focus to three cancer programs
The Joint stock heads into earnings release after market close
Onterris stock in focus after Q3 profit rises as revenue falls
Invivyd stock: Biotech grants options to new employees
Fate Therapeutics stock: New hires receive 300,000 options
Li-Metal stock follows proposed investment pivot after filing
Kandi Technologies stock completes 1-for-10 reverse split
1-800-FLOWERS.COM stock faces earnings test after softer quarter
NN stock: Company raises 2026 outlook after strong Q3
Inhibrx Biosciences stock faces a busy clinical-data calendar
Lennox stock faces lower outlook after third-quarter margin pressure
Nvidia's Cloud Rulebook Is Being Rewritten in Real Time — and the 17 November Call Won't Settle It
Rheinmetall's Strong Quarter Meets a Softer Year as Arminius Slips
Rolls-Royce's Technical Wins Face a Customer's Verdict
Iveda stock heads toward November 10 GX11 flight demonstration
El Condor stock: Q2 profit returns as revenue falls 26%
Mundial stock: Q2 revenue rises as loss narrows
OneSpan stock: Q3 growth backs higher 2026 outlook
Hyliion stock: Q3 results set for November 10
ParkOhio stock draws focus as company raises 2026 outlook
Glaukos stock gets a stronger 2026 outlook after Q3 growth
Pure Storage stock trades at Lang & Schwarz before fiscal results
Full House Resorts stock faces debt clarity test before results
Fidelity National Financial stock faces pressure from falling premiums
Multiplan stock: R$1 billion mall sales cut leverage
Estée Lauder stock gains momentum as outlook rises after Q1 recovery
Intrusion stock faces Nasdaq hurdle after $4 million debt swap
ProPhase Labs stock: Venkatesan reports 5.48% stake
Immunome stock: IM-1021 shows 53% lymphoma response rate
nCino stock approaches December earnings after AI suite launch
LVMH Climbs 4.5% as Sector Tailwind Outruns a Downgrade and a French Probe
Hensoldt's Warehouse Headache Meets a Valuation Wall Ahead of Two November Dates
Lenzing Investors Get Their Answer Day After a 5.4% Run-Up